Global Central Nervous System Partnering 2016-2023: Full Collection of Deals Signed by the World's Pharma and Biotechnology Companies
2023-05-11
DUBLIN, May 11, 2023 /PRNewswire/ -- The "Global Central Nervous System Partnering 2016-2023: Deal trends, players and financials" report has been added to
ResearchAndMarkets.com's offering.
Global Central Nervous System Partnering 2016 to 2010 provides the full collection of central nervous system disease deals signed between the world's pharmaceutical and biotechnology companies since 2016.
Trends in central nervous system partnering deals
Financial deal terms for headline, upfront and royalty by stage of development
Central Nervous System partnering agreement structure
Central Nervous System partnering contract documents
Top central nervous system deals by value
Most active central nervous system dealmakers
Most of the deals included within the report occur when a licensee obtains a right or an option right to license a licensor's product or technology. More often these days these deals tend to be multi-component including both a collaborative R&D and a commercialization of outcomes element.
The report takes readers through the comprehensive central nervous system disease deal trends, key players and top deal values allowing the understanding of how, why and under what terms companies are currently entering central nervous system deals.
The report presents financial deal terms values for central nervous system deals, where available listing by overall headline values, upfront payments, milestones and royalties enabling readers to analyse and benchmark the value of current deals.
The initial chapters of this report provide an orientation of central nervous system dealmaking trends.
Chapter 1 provides an introduction to the report.
Chapter 2 provides an overview of the trends in central nervous system dealmaking since 2016 covering trends by year, deal type, stage of development, technology type and therapeutic indication.
Chapter 3 includes an analysis of financial deal terms covering headline value, upfront payment, milestone payments and royalty rates.
Chapter 4 provides a review of the leading central nervous system deals since 2016. Deals are listed by headline value. The chapter includes the top 25 most active central nervous system dealmakers, together with a full listing of deals to which they are a party. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.
Chapter 5 provides comprehensive access to central nervous system deals since 2016 where a deal contract is available, providing the user with direct access to contracts as filed with the SEC regulatory authorities. Each deal title links via Weblink to an online version of the deal record contract document, providing easy access to each contract document on demand.
Chapter 6 provides a comprehensive directory of all central nervous system partnering deals by specific central nervous system target announced since 2016. The chapter is organized by specific central nervous system therapeutic target. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.
In addition, a comprehensive appendix is provided with each report of all central nervous system partnering deals signed and announced since 2016. The appendices are organized by company A-Z, stage of development at signing, deal type (collaborative R&D, co-promotion, licensing etc) and technology type. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.
The report also includes numerous tables and figures that illustrate the trends and activities in central nervous system partnering and dealmaking since 2016.
In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of central nervous system technologies and products.
Report scope
Global Central Nervous System Partnering 2016 to 2023 is intended to provide the reader with an in-depth understanding and access to central nervous system trends and structure of deals entered into by leading companies worldwide.
Global Central Nervous System Partnering 2016 to 2023 includes:
Trends in central nervous system dealmaking in the biopharma industry since 2016
Access to headline, upfront, milestone and royalty data
Access to hundreds of central nervous system deal contract documents
Comprehensive access to over 1,700 central nervous system deal records
The leading central nervous system deals by value since 2016
Most active central nervous system dealmakers since 2016
The report includes deals for the following indications: Cerebral palsy, Creutzfeldt Jakob disease, Dizziness, Epilepsy, Faints, Falls, Guillain Barre syndrome, Headache, Meningitis (Bacterial, Meningococcal, Pneumococcal), Mycobacterium tuberculosis (TB), Haemophilus influenzae Type B (Hib), Migraine, Motor Neurone Disease (Amyotrophic Lateral Sclerosis/Lou Gehrig's Disease, Multiple sclerosis, Nausea, Neuropathy, Pain, Neuralgia, Fibromyalgia, Paralysis, Parkinson's disease, Restless leg syndrome, Spinal cord, Stroke, Stuttering, Traumatic Brain Injury, Vertigo, Weakness, plus other CNS indications.
In Global Central Nervous System Partnering 2016 to 2023, available deals and contracts are listed by:
Headline value
Upfront payment value
Royalty rate value
Stage of development at signing
Deal component type
Technology type
Specific therapy indication
Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.
The Global Central Nervous System Partnering 2016-2023 report provides comprehensive access to available deals and contract documents for over 1,700 central nervous system deals.
Analyzing actual contract agreements allows assessment of the following:
What are the precise rights granted or optioned?
What is actually granted by the agreement to the partner company?
What exclusivity is granted?
What is the payment structure for the deal?
How are the sales and payments audited?
What is the deal term?
How are the key terms of the agreement defined?
How are IPRs handled and owned?
Who is responsible for commercialization?
Who is responsible for development, supply, and manufacture?
How is confidentiality and publication managed?
How are disputes to be resolved?
Under what conditions can the deal be terminated?
What happens when there is a change of ownership?
What sublicensing and subcontracting provisions have been agreed?
Which boilerplate clauses does the company insist upon?
Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
Which jurisdiction does the company insist upon for agreement law?
Selection of Companies Mentioned
2M
3PrimeDx
4SC Discovery
7D Surgical
A*STAR Agency for Science
Technology and Research
Ab Medica
Abzena
Accelerated Cure Project for MS
Accelovance
Accera Pharmaceuticals
Actavis (acquired by Watson)
Acturum Life
Adaptive Health
Adept Neuro
Advanced Cooling Therapy
Advantage Consumer Healthcare
AEterna Zentaris
Affilogic
AFFiRiS
Aguettant
AKC Canine Health Foundation
Aleva Neurotherapeutics
Alfa Wassermann
Alkahest
Alkermes
Allergan
ALS Association
ALS Finding a Cure Foundation
Altair
Altus Formulation
Alzheimer's Association
Alzheimer's Drug Discovery Foundation
Alzheimers Research UK
American Association of Neuromuscular & Electrodiagnostic Medicine
American College of Physicians Foundation
American Heart/Stroke Association
American Heart Association
American Migraine FoundationMigraine Foundation
American National Multiple Sclerosis Society
American Parkinson Diseases Association
American Speech-Language-Hearing Association
AmorChem
Amylgen
Annette Funicello Research Fund for Neurological Diseases (AFRFND)
Antidote
Aphios
AppliedVR
Aptahem
Aptinyx
arGEN-X
Arterys
Asceneuron
Aspen Holding
Association for Frontotemporal Degeneration
Astellas Pharma Europe
Ataxion
Aurora Cannabis
Australian Imaging
Biomarker & Lifestyle Flagship Study of Ageing (AIBL)
Australian Research Council
Bachem
Bachmann-Strauss Dystonia & Parkinson Foundation
Baudry Laboratory
Bayer
B Braun
BD Consultancy
Becton Dickinson
Berg
Best Choice
Beyond Batten Disease Foundation
Bhang
Bial
BIA Separations
BIOCORP
BioCrossroads
Biodirection
Biohealth Innovation
Bioinn Molecular Diagnosis
BioMed X Innovation Center
Bionomics
Bionure
Biopharmaceuticals Australia
BioSyent Pharma
Blackfynn
Blackrock NeuroMed
Blinktbi
Bracket
BRAIN Initiative
BrainLAB
BrainScope
Brainsway
Brain Treatment Center San Diego
Breathe Active
Bruker
Cal-BRAIN
California Institute for Regenerative Medicine
Calox de Costa Rica
Camarus
Cambridge Cognition
Cambridge Commodities
Camino Partnership
Canadian Physiotherapy Association
Canigma
CannaKids
CannaRoyalty
Cellectricon
Celltrion
Cellvation
Center for iPS Cells Research and Application
Center for Sensorimotor Neural Engineering
Center for Technology and Innovation in Pediatrics (CTIP)
Center for the Advancement of Science in Space
Centinel Spine
Centre for Commercialization of Regenerative Medicine (CCRM)
Centre Hospital University - Bordeaux
Centro de Investigacion Biomedica en Red de Salud Mental
CereHealth
Certainty Health
Charcot-Marie-Tooth Association
Charles River Associates
Children's Hospital of Pittsburgh Foundation
Children's Hospital Of Wisconsin
Children's Minnesota
Christie Medical
Christopher & Dana Reeve Foundation
Chromocell
Cipla Medpro
Citizens United for Research in Epilepsy
City of Hope
Clene Nanomedicine
Cleveland Clinic
Clinatec
Clinical Ink
Clinical Laserthermia Systems (CLS)
Clinical Network Services
Clinvest
CluePoints
CogState
Cohen Veterans Bioscience
Colorado HealthOP
CombiGene
Compassionate Care Center of New York
Compass Point Research
Compumedics
Congressman Chaka Fattah
Corsair Innovations
Cortexyme
Creatori Health
Department of Health and Human Services
Department of Veterans Affairs
DiamiR
Diego Pellicer
Dixi
DKSH
Doctor's Medical
Dr. Reddy's Laboratories
Dr. Stephen Cook
DrChrono
Duke-NUS Graduate Medical School Singapore
Durect
DyNAbind
Dystonia Europe
DZNE German Center for Neurodegenerative Diseases
Early Signal Foundation
EDAP TMS
eemagine
Egalet
Electrical Geodesics
ElectroCore
Elekta
EMMAC Life Sciences
EMS
Emulate
Enamine
Epilepsy Foundation (EF)
Epilepsy Society
Esteve
Eureka Eurostars
Euroimmun
European Commission
European Parkinson's Disease Association
European Union
Evidation Health
Exeltis
Expesicor
F-Star
Fast Forward
FastFunds Financial
Federal Ministry of Education and Research (BMBF)
FightMND
Flint Rehabilitation Devices
Florey Institute of Neuroscience and Mental Heath
Florida Atlantic University Research
Flywheel
Fondazione Telethon
Forbius
Foundation For Angelman Syndrome TherapeuticsAngelman Syndrome Therapeutics
Foundation for Mitochondrial Medicine
Foundation for the National Institutes of Health (FNIH)
Fritz Clinic
Fundacion Universidad Torcuato Di Tella
Galen
GeneData
General Electric (GE)
Genomics
Geo-Med
Gestion Univalor
Global Alliance for Innovation in Neuroscience
Global Drug Development Centre (GDCC) China
And More
For more information about this report visit https://www.researchandmarkets.com/r/ovkn39
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Media Contact:
Research and Markets
Laura Wood, Senior Manager
[email protected]
For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Logo - https://mma.prnewswire.com/media/539438/Research_and_Markets_Logo.jpg
SOURCE Research and Markets
更多内容，请访问原始网站
文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。
靶点
-来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。